Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.

Cancer research - 15 Jul 2015

Stewart Michelle L, Tamayo Pablo, Wilson Andrew J, Wang Stephanie, Chang Yun Min, Kim Jong W, Khabele Dineo, Shamji Alykhan F, Schreiber Stuart L

Abstract excerpt

Decitabine, a cancer therapeutic that inhibits DNA methylation, produces variable antitumor response rates in patients with solid tumors that might be leveraged clinically with identification of a predictive biomarker. In this study, we profiled the response of human ovarian, melanoma, and breast cancer cells treated with decitabine, finding that RAS/MEK/ERK pathway activation and DNMT1 expression correlated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azacitidine
Share to Cystadenocarcinoma, Serous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decitabine

Share to Drug Resistance, Neoplasm

Share to Genes, ras

Share to Mice, Nude

Share to Ovarian Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 25968887
DOI: 10.1158/0008-5472.CAN-14-2860
PMCID: PMC4506246

Genes

KRAS
DNMT1
BNIP3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.PMID 25968887Read ↗

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.Semantic proximity Read ↗

Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient.Semantic proximity Read ↗

Decitabine limits escape from MEK inhibition in uveal melanomaSemantic proximity Read ↗

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.Semantic proximity Read ↗

Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study.Semantic proximity Read ↗

Increased IFNγ+ T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor TherapySemantic proximity Read ↗

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Semantic proximity Read ↗

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS -Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibSemantic proximity Read ↗

Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease modelsSemantic proximity Read ↗

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaSemantic proximity Read ↗

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK InhibitionSemantic proximity Read ↗

Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.